[Research sponsored by the industry benefits scientific progress].
The conflicts of interest dominate discussions on collaborative research between academic institutions and the pharmaceutical industry. Although one should not be blind to such possibilities and remain critical, the advantages outweigh the risks by far. The remaining diseases for which adequate pharmacotherapy is lacking are complex and require an expensive research infrastructure. Therefore, progress will benefit from collaboration and should not be hindered by short-sightedness.